COURT-RULING filed Jul 27, 2026 at 20:00 ET
The District of New Jersey partially denied Novo Nordisk's motion to dismiss a securities class action, allowing claims to proceed that Novo misled investors by not disclosing a flexible dosing protocol in its CagriSema REDEFINE 1 trial when making statements about the drug's tolerability. The ruling keeps Novo and its EVP of Development Martin Lange as defendants on three specific tolerability-related statements, while dismissing most other claims including those against former CEO Jørgensen. The litigation overhang persists, but the core adverse information has been public since December 2024 when the stock fell 17.8%.